This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
The Central Dogma. This states that once "information" has passed into protein it cannot get out again. In more detail, the transfer of information from nucleic acid to nucleic acid, or from nucleic acid to protein may be possible, but transfer from protein to protein, or from protein to nucleic acid is impossible. Information here means the precise determination of sequence, either of bases in the nucleic acid or of amino acid residues in the protein. He re-stated it in a Nature paper published in 1970: "The central dogma of molecular biology deals with the detailed residue-by-residue transfer of sequential information. It states that such information cannot be transferred back from protein to either protein or nucleic acid." A second version of the central dogma is popular but incorrect. This is the simplistic DNA → RNA → protein pathway published by James Watson in the first edition of The Molecular Biology of the Gene (1965). Watson's version differs from Crick's because Watson describes a two-step (DNA → RNA / RNA → protein) process as the central dogma. While the dogma as originally stated by Crick remains valid today, Watson's version does not.
In 2000, crews organized by Jack Horner discovered five Tyrannosaurus skeletons near the Fort Peck Reservoir. In 2001, a 50% complete skeleton of a juvenile Tyrannosaurus was discovered in the Hell Creek Formation by a crew from the Burpee Museum of Natural History. Dubbed Jane (BMRP 2002.4.1), the find was thought to be the first known skeleton of a pygmy tyrannosaurid, Nanotyrannus, but other researchers considered it as the most complete juvenile T. rex; currently exhibited at the Burpee Museum of Natural History, Jane is now re-described as the holotype of N. lethaeus. In 2002, a skeleton nicknamed "Wyrex", discovered by amateur collectors Dan Wells and Don Wyrick, had 114 bones and was 38% complete. The dig was concluded in 2004 by the Black Hills Institute with the first live online Tyrannosaurus excavation. In 2006, Montana State University revealed that it possessed the largest Tyrannosaurus skull yet discovered (from a specimen named MOR 008), measuring 5 feet (152 cm) long. Subsequent comparisons indicated that the longest head was 136.5 centimetres (53.7 in) (from specimen LACM 23844) and the widest head was 90.2 centimetres (35.5 in) (from Sue).
== Export == GS-HNE is a potent inhibitor of the activity of glutathione S-transferase, and therefore must be shuttled out of the cell to allow conjugation to occur at a physiological rate. Ral-interacting GTPase activating protein (RLIP76, also known as Ral-binding protein 1), is a membrane-bound protein which has high activity towards the transport of GS-HNE from the cytoplasm to the extracellular space. This protein accounts for approximately 70% of such transport in human cell lines, while the remainder appears to be accounted for by Multidrug Resistance Protein 1 (MRP1).
Sources: en.wikipedia.org
=== "Ferocious" Lactobacillus === In the late 20th century, among American winemakers, seemingly healthy fermentation were reported becoming rapidly inundated with high levels of acetic acid that overcame wine yeasts and led to stuck fermentations. While a novel species of Acetobacter or wine spoilage yeast was initially thought to be the culprit, it was eventually discovered to be several species of Lactobacillus, L. kunkeei, L. nagelii, and L. hilgardii, collectively nicknamed "ferocious" Lactobacillus for their aggressive acetic acid production, how quickly they multiply, and their high tolerance to sulfur dioxides and other microbiological controls. Ferments of high-pH wines (greater than 3.5) that spent time cold soaking prior to yeast inoculations and received little to no sulfur dioxide during crushing seem to be at the most risk for "ferocious" Lactobacillus. While infection seems to be vineyard-specific, currently, none of any of the implicated lactobacilli has been reported as being found on the surface of freshly harvested wine grapes.
=== Protandim voluntary recall === In December 2012, LifeVantage issued a voluntary recall of select lots (ten lots in total comprising 247,896 bottles) of Protandim due to potential health risks arising from the possible inclusion of small metal fragments in the final product. In February 2013, the company announced that it was extending the recall to include additional lots of the product, estimating the total cost of the recall at $5.9 million.
=== Taiwan === In October 2006, Taiwan banned ractopamine along with other beta-adrenergic agonists. In a 2012 climb-down, its legislature passed amendments to its Act Governing Food Sanitation, authorising government agencies to set safety standards for ractopamine. The Taiwanese Department of Health ultimately established an MRL of 10 ppb for ractopamine in beef on 31 July 2012. The American Institute in Taiwan, which represents US interests in Taiwan, states that these "and many other countries have determined that meat from animals fed ractopamine is safe for human consumption"; this is in the context of an ongoing trade dispute between Taiwan and the US on this subject, which threatened to prevent Taiwan's entry to the Trans-Pacific Partnership trade pact. In 2020, restrictions on imports of US pork with ractopamine were relaxed, leading to protests. A referendum took place on December 18, 2021, deciding whether to ban the import of pork with ractopamine, and the ban was rejected.
Sources: en.wikipedia.org
A peptide library is a tool for studying proteins. Peptide libraries typically contain a large number of peptides that have a systematic combination of amino acids. Usually, solid phase synthesis, e.g. resin as a flat surface or beads, is used for peptide library generation. Peptide libraries are a popular tool for experiments in drug design, protein–protein interactions, and other biochemical and pharmaceutical applications. Synthetic peptide libraries are synthesized without utilizing biological systems such as phage or in vitro translation. There are at least five subtypes of synthetic peptide libraries that differ from each other by the design of the library and/or the method used for the synthesis of the library. The subtypes include:
In some areas food crops were eradicated to make way for opium, contributing to famines in Guizhou and Shaanxi Provinces between 1921 and 1923, and food deficits in other provinces. Beginning in 1915, Chinese nationalist groups came to describe the period of military losses and Unequal Treaties as the "Century of National Humiliation", later defined to end with the conclusion of the Chinese Civil War in 1949. In the northern provinces of Ningxia and Suiyuan in China, Chinese Muslim General Ma Fuxiang both prohibited and engaged in the opium trade. It was hoped that Ma Fuxiang would have improved the situation, since Chinese Muslims were well known for opposition to smoking opium. Ma Fuxiang officially prohibited opium and made it illegal in Ningxia, but the Guominjun reversed his policy; by 1933, people from every level of society were abusing the drug, and Ningxia was left in destitution. In 1923, an officer of the Bank of China from Baotou found out that Ma Fuxiang was assisting the drug trade in opium which helped finance his military expenses. He earned US$2 million from taxing those sales in 1923. General Ma had been using the bank, a branch of the Government of China's exchequer, to arrange for silver currency to be transported to Baotou to use it to sponsor the trade. The opium trade under the Chinese Communist Party was important to its finances in the 1940s. Peter Vladimirov's diary provided a first hand account. Chen Yung-fa provided a detailed historical account of how the opium trade was essential to the economy of Yan'an during this period.
== Side effects and label warnings == The most common side effects are nausea, fatigue, vomiting, alopecia (hair loss), constipation, decreased appetite, anemia (hemoglobin in blood is below the reference range), decreased neutrophil count (white blood cells that help lead the body's immune system response to fight infection), diarrhea, leukopenia (other white blood cells that help the immune system), cough and decreased platelet count (component of blood whose function is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot). The prescribing information for trastuzumab deruxtecan includes a boxed warning about the risk of interstitial lung disease (a group of lung conditions that causes scarring of lung tissues) and embryo-fetal toxicity. Interstitial lung disease and pneumonitis, including cases resulting in death, have been reported with trastuzumab deruxtecan.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.